Elvitegravir for the treatment of HIV.

about

Precision medicine for HIV: where are we?Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco.Recent advances in the discovery of small-molecule inhibitors of HIV-1 integrase

P2860

Q47569821-E011D9F8-E419-45CC-A479-628E37D8D585 Q55446383-B6709E80-D0D4-415D-B286-19537F5D703F Q58760446-A6EBC530-BAD9-48F2-9236-ACD6DF2F026B

P2860

Elvitegravir for the treatment of HIV.

Item

http://www.wikidata.org/entity/Q38987327

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Elvitegravir for the treatment of HIV.

@en

type

Item

label

Elvitegravir for the treatment of HIV.

@en

prefLabel

Elvitegravir for the treatment of HIV.

@en

P1476

Elvitegravir for the treatment of HIV

@en

P2093

Jamie J Kisgen

http://www.w3.org/2001/XMLSchema#string

Lindsey M Childs-Kean

http://www.w3.org/2001/XMLSchema#string

Marylee V Worley

http://www.w3.org/2001/XMLSchema#string

Nathan R Unger

http://www.w3.org/2001/XMLSchema#string

P2860

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials

Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.

HIV integrase, a brief overview from chemistry to therapeutics.

Tolerability of HIV integrase inhibitors.

Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques

Patient-Reported Symptoms Over 48 Weeks in a Randomized, Open-Label, Phase IIIb Non-Inferiority Trial of Adults with HIV Switching to Co-Formulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF versus Continuation of Non-Nucleoside Rever

Patient-Reported Symptoms over 48 Weeks in a Randomized, Open-Label, Phase 3b Non-inferiority Trial of Adults with HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir DF Versus Continuation of Ritonavir-Boosted Prote

Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study

P304

2359-2370

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14656566.2016.1250885

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth M Sherman

P577

2016-10-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27767362

http://www.w3.org/2001/XMLSchema#string

Elvitegravir for the treatment of HIV.

about

P2860

P2860

Elvitegravir for the treatment of HIV.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698